(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
21 June 2012 (21.06.2012)

WIPO | PCT

(10) International Publication Number
WO 2012/079878 A3

(51) International Patent Classification:
A61K 39/00 (2006.01) *C07K 14/705* (2006.01)
C07K 14/47 (2006.01)

(21) International Application Number:
PCT/EP2011/070024

(22) International Filing Date:
14 November 2011 (14.11.2011)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
PCT/EP2010/069675
14 December 2010 (14.12.2010) EP

(71) Applicant *(for all designated States except US)*: **IMMATICS BIOTECHNOLOGIES GMBH** [DE/DE]; Paul-Ehrlich-Strasse 15, 72076 Tuebingen (DE).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **WEINSCHENK, Toni** [DE/DE]; Im Morgenrain 15, 73773 Aichwald (DE). **LEWANDROWSKI, Peter** [DE/DE]; Burgstrasse 14, 72070 Tuebingen-Hirschau (DE). **RAMMENSEE, Hans-Georg** [DE/DE]; Sommerhalde 3, 72070 Tübingen (DE). **STEVANOVIC, Stefan** [DE/DE]; Auf der Burg 3, 72074 Tübingen (DE). **GOUTTEFANGEAS, Cécile** [FR/DE]; Mauerstrasse 19b, 72070 Tübingen (DE).

(74) Agent: **KRAUSS, Jan, B.**; Boehmert & Boehmert, Pettenkoferstrasse 20 - 22, 80336 Munich (DE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU,

[Continued on next page]

(54) Title: HLA-BINDING PEPTIDES DERIVED FROM PROSTATE-ASSOCIATED ANTIGENIC MOLECULES AND METHODS OF USE THEREOF

Figure 1

Protein	Pos.	Sequence	SEQ ID NO
PSA	141-150	FLTPKKLQCV	1
	146-154	KLQCVDLHV	2
	154-163	VISNDVCAQV	3
PSCA	14-22	ALQPGTALL	4
	105-113	AILALLPAL	5
PSMA	4-12	LLHETDSAV	6
	711-719	ALFDIESKV	7
Survivin	95-104	ELTLGEFLKL	8
	5-14	TLPPAWQPFL	9
TRP-P8	187-195	GLMKYIGEV	10
PROSTEIN	31-39	CLAAGITYV	11
Influenza MP	58-66	GILGFVFTL	12
PSMA	459-473	NYTLRVDCTPLMYSL	13
Survivin	97-111	TLGEFLKLDRERAKN	14

(57) Abstract: Methods and compositions for immunotherapeutic treatment of prostate cancer are disclosed. More specifically methods of treating patients with prostate cancer comprising administering compositions comprising HLA-binding peptides derived from prostate-associated antigenic molecules, either with or without immunological adjuvants, are disclosed.

WO 2012/079878 A3

TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

— *with sequence listing part of description (Rule 5.2(a))*

(88) Date of publication of the international search report:
9 August 2012